Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Bone is the primary anatomical site of breast cancer metastasis, and bone metastasis is associated with increased morbidity and mortality. Mesenchy‐mal stem cells (MSC) are a predominant fibroblast cell population within the bone marrow, and metastatic breast cancer cells that seed within bone would predictably encounter MSC or their soluble factors. Therefore, we examined the impact of primary human MSC on a panel of estrogen receptor‐alpha (ERα)‐positive (MCF‐7, T47D, BT474, and ZR‐75–1) and ERα‐negative (MDA‐MB‐231 and MDA‐MB‐468) human breast tumor cell lines. All ERα‐positive breast tumor cell lines displayed low basal activation of signal transducer and activator of transcription 3 (STAT3) until exposed to MSC, which induced chronic phosphorylation of STAT3 on tyrosine‐705. Paracrine IL‐6 was found to be the principal mediator of STAT3 phosphorylation in coculture studies, and MSC induction of STAT3 phos‐phorylation was lost when IL‐6 was depleted from MSC conditioned media or the IL‐6 receptor was blocked on tumor cells. Enhanced tumor cell growth rates were observed in the ERα‐positive mammary tumor cell line MCF‐7 after paracrine and autocrine IL‐6 exposure, where MCF‐7 growth rates were enhanced by > 2‐fold when cocultured with MSC in vitro and even more pronounced in vivo with autocrine IL‐6 production.—Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., Hall, B. M. Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer. FASEB J. 21, 3763–3770 (2007)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-6 is an MSC-secreted inflammatory cytokine displaying pro-survival, pro-growth and pro-angiogenic activities [11], which has been implicated in tumor progression of various cancers including breast cancer [113, 114].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [113]
In the citing paper
“The production of trophic factors from MSCs including VEGF, chemokine CCL5 and IL6 (activation STAT-3) has been connected with tumour growth and metastasis in Burkitt's lymphoma, breast cancer, colonic cancer and chronic myeloid leukaemia [69], [70], [71], [72], [73].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [70]
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“Mesenchymal stem cells (MSC), also referred to as bone marrow stromal cells, are a common fibroblastic cell population within bone that regulates hematopoiesis, has a robust ability to self-renew, can differentiate into multiple mesenchymal cell lineages, and constitutively produces IL-6 ( 14 , 15).”
BackgroundCaplan, A. I. (1991) · Journal of Orthopaedic Research · doi:10.1002/jor.1100090504 · Cited by 6,548
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“A growing body of evidence demonstrates that stromal cell fibroblasts are influential players in tumor progression and metastasis ( 9 ).”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 3×
“Signal transducer and activator of transcription 3 (STAT3) is one of the primary intracellular targets activated after exposure to IL-6 (18), and STAT3 activation has been connected with enhanced tumor cell growth, survival, and immune evasion in breast cancer (22–24).”
BackgroundInfluentialCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · cited 1×
“cancers including multiple myeloma (19), prostate”
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability
Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Angela Nieto, M., et al. (2005) · Nature · doi:10.1038/nature03688 · Cited by 1,284
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994 · cited 1×
“, C57BL/6, and FVB/N) as described (26) and maintained in RPMI 1640 complete media.”
BackgroundSelf-citationThe role of IL-6 and STAT3 in inflammation and cancer
Hodge, D. R., Hurt, E. M., & Farrar, W. L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.016 · Cited by 950 · cited 1×
“Of interest, the bone marrow microenvironment in postmenopausal women maintains stable levels of IL-6 protein, regardless of systemic estradiol levels (33); therefore, it is possible that the bone marrow microenvironment may represent a more favorable tissue for IL-6-responsive ER -positive tumor cells (32, 34).”
Background
Cited by
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
“For example, interleukin-6 (IL6) is upregulated in epithelial cancers such as breast and prostate (Sasser et al., 2007; Wegiel et al., 2008).”
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
“For example, although IL-6 secretion occurs in ER breast cancer cells, no IL-6 expression is detected in various ER+ breast cancer cell lines (Sasser et al., 2007) or in A375 melanoma.”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Self-citationInterleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
“IL-6 is a pleiotropic cytokine that participates in acute inflammation as the major inducer of C-reactive protein, plays a central role in hematopoiesis (Kishimoto, 2006), and enhances proliferation of breast cancer cells (Sasser et al., 2007b).”
BackgroundMethodResultInfluentialSelf-citationConstitutive activation of STAT 3 in breast cancer cells: A review
Banerjee, K., & Resat, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.29923 · Cited by 611
Sethi, N., Dai, X., Winter, C. G., & Kang, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.022 · Cited by 577
“IL-6 is associated with a poor prognosis in breast cancer (Salgado et al., 2003) and is capable of supporting tumor growth in the bone microenvironment (Sasser et al., 2007).”
BackgroundThe Role of Cytokines in Breast Cancer Development and Progression
Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I., & Morales-Montor, J. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0026 · Cited by 490
Ortiz-Montero, P., Londoño-Vallejo, A., & Vernot, J.-P. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0172-3 · Cited by 428
Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?
Grivennikov, S., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.020 · Cited by 368
“These two studies significantly expand our understanding of IL-6 involvement in epithelial cancers and stress the importance of autocrine/paracrine IL-6 signaling along with the work of others (Sasser et al., 2007; Yeh et al., 2006).”
BackgroundWalter, M., Liang, S., Ghosh, S., Hornsby, P. J., & Li, R. (2009) · Oncogene · doi:10.1038/onc.2009.130 · Cited by 312
“This finding is in line with previously published data showing the growth-promoting effect of IL-6 (Paduch and Kandefer-Szerszen, 2005; Sasser et al., 2007).”
ResultConcise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit?
Lazennec, G., & Jorgensen, C. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1006 · Cited by 255
The wound healing, chronic fibrosis, and cancer progression triad
Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2013 · Cited by 253
Stock, K., Estrada, M. F., Vidic, S., Gjerde, K., Rudisch, A., Santo, V. E., Barbier, M., Blom, S., Arundkar, S. C., Selvam, I., et al. (2016) · Scientific Reports · doi:10.1038/srep28951 · Cited by 253
The immune system and inflammation in breast cancer
Jiang, X., & Shapiro, D. J. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.06.003 · Cited by 240
“For instances, IL-6 promotes proliferation as well as aggressive phenotype of ERα+ breast cancer cells (Sasser et al., 2007, Sullivan et al., 2009); IL-1β reverses the suppression of estrogen target genes by SERM (Zhu et al., 2006), suggesting IL-1β may be directly associated with resistance to…”
BackgroundStudebaker, A. W., Storci, G., Werbeck, J. L., Sansone, P., Sasser, A. K., Tavolari, S., Huang, T., Chan, M. W. Y., Marini, F. C., Rosol, T. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0400 · Cited by 229
Self-citationBharti, R., Dey, G., & Mandal, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.048 · Cited by 228
Incio, J., Ligibel, J. A., McManus, D. T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S. M., Vardam, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0945 · Cited by 222
Cai, Z., Sanchez, A., Shi, Z., Zhang, T., Liu, M., & Zhang, D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1993 · Cited by 214
Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model
Sun, B., Roh, K.-H., Park, J.-R., Lee, S.-R., Park, S.-B., Jung, J.-W., Kang, S.-K., Lee, Y.-S., & Kang, K.-S. (2009) · Cytotherapy · doi:10.1080/14653240902807026 · Cited by 214
Okuda, H., Kobayashi, A., Xia, B., Watabe, M., Pai, S. K., Hirota, S., Xing, F., Liu, W., Pandey, P. R., Fukuda, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1678 · Cited by 201
The Role of the Estrogen Pathway in the Tumor Microenvironment
Rothenberger, N., Somasundaram, A., & Stabile, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020611 · Cited by 190
The Role of Breast Cancer Stem Cells in Metastasis and Therapeutic Implications
Velasco-Velázquez, M. A., Popov, V. M., Lisanti, M. P., & Pestell, R. G. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.03.005 · Cited by 178
Obesity-associated Breast Cancer: Analysis of risk factors
Engin, A. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-48382-5_25 · Cited by 178
Rowan, B. G., Gimble, J. M., Sheng, M., Anbalagan, M., Jones, R. K., Frazier, T. P., Asher, M., Lacayo, E. A., Friedlander, P. L., Kutner, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089595 · Cited by 174
Baumgarten, S. C., & Frasor, J. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1302 · Cited by 172
Mesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
Influence of IL-8 on The Epithelial–Mesenchymal Transition and the Tumor Microenvironment
Palena, C., Hamilton, D. H., & Fernando, R. I. (2012) · Future Oncology · doi:10.2217/fon.12.59 · Cited by 166
“IL-6 is a well-known regulator of immune responses and a major contributor to the pathogenesis of various autoimmune and inflammatory diseases [34], and it has also been implicated as a potent growth factor for certain tumor cell types, including breast cancer cells [35].”
BackgroundRecent advances in understanding tumor stroma-mediated chemoresistance in breast cancer
Plava, J., Cihova, M., Burikova, M., Matuskova, M., Kucerova, L., & Miklikova, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0960-z · Cited by 164
Oh, K., Lee, O.-Y., Shon, S. Y., Nam, O., Ryu, P. M., Seo, M. W., & Lee, D.-S. (2013) · Breast Cancer Research · doi:10.1186/bcr3473 · Cited by 156
“Mesenchymal stem cells constitute the cancer stem cell niche by providing IL-6 and CXCL7 [45,46].”
BackgroundGenetic Engineering of Mesenchymal Stem Cells and Its Application in Human Disease Therapy
Hodgkinson, C. P., Gomez, J. A., Mirotsou, M., & Dzau, V. J. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.165 · Cited by 150
“For example, IL-6 and CCL5, proteins produced by MSCs, have been shown to increase the growth and metastasis of breast cancer cells, respectively (Karnoub et al. , 2007; Sasser et al. , 2007).”
Hill, B. S., Sarnella, A., D’Avino, G., & Zannetti, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.028 · Cited by 156
Lederle, W., Depner, S., Schnur, S., Obermueller, E., Catone, N., Just, A., Fusenig, N. E., & Mueller, M. M. (2011) · International Journal of Cancer · doi:10.1002/ijc.25621 · Cited by 139
Vecchione, R., Quagliariello, V., Calabria, D., Calcagno, V., Luca, E. D., Iaffaioli, R. V., & Netti, P. A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.004 · Cited by 129
Zhou, J., Ong, C. N., Hur, G. M., & Shen, H. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.014 · Cited by 133
Hollingshead, B. D., Beischlag, T. V., DiNatale, B. C., Ramadoss, P., & Perdew, G. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6168 · Cited by 128
“MCF-7 cells exhibit very low constitutive expression of IL-6 in contrast to some other breast cancer lines, such as MDA-MB-231 (24).”
BackgroundResultInfluentialHuang, C.-K., Chang, P.-H., Kuo, W.-H., Chen, C.-L., Jeng, Y.-M., Chang, K.-J., Shew, J.-Y., Hu, C.-M., & Lee, W.-H. (2017) · Nature Communications · doi:10.1038/ncomms14706 · Cited by 117
Recent discoveries concerning the tumor - mesenchymal stem cell interactions
Lazennec, G., & Lam, P. Y. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.10.004 · Cited by 117
The association between obesity related adipokines and risk of breast cancer: a meta-analysis
Gui, Y., Pan, Q., Chen, X., Xu, S., Luo, X., & Chen, L. (2017) · Oncotarget · doi:10.18632/oncotarget.17853 · Cited by 132
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
Dieci, M. V., Griguolo, G., Miglietta, F., & Guarneri, V. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.011 · Cited by 123
“However, breast fibroblasts in the primary tumor site as well as bone mesenchymal stem cells in metastatic sites produce IL6 which may act as a paracrine stimulus on HR+ BC cells [33,34].”
BackgroundMammary Gland Growth Factors: Roles in Normal Development and in Cancer
Hynes, N. E., & Watson, C. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003186 · Cited by 146
“IL-6 has been shown also to 12 Cite this article as Cold Spring Harb Perspect Biol 2010;2:a003186 be a potent growth factor in ERa positive breast tumors (Sasser et al. 2007).”
BackgroundDe Luca, A., Gallo, M., Aldinucci, D., Ribatti, D., Lamura, L., D'Alessio, A., De Filippi, R., Pinto, A., & Normanno, N. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22548 · Cited by 113
“It has been previously demonstrated that IL-6 and VEGF can sustain the growth of different breast cancer cell lines including MCF-7 cells, which express receptors for both these growth factors (Sasser et al., 2007;Wu et al., 2006; Sullivan et al., 2009).”
BackgroundBurns, K. A., Thomas, S. Y., Hamilton, K. J., Young, S. L., Cook, D. N., & Korach, K. S. (2018) · Endocrinology · doi:10.1210/en.2017-00562 · Cited by 113
Stem cells as vectors for antitumour therapy
Loebinger, M. R., & Janes, S. M. (2010) · Thorax · doi:10.1136/thx.2009.128025 · Cited by 109
DiNatale, B. C., Schroeder, J. C., Francey, L. J., Kusnadi, A., & Perdew, G. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.118570 · Cited by 109
The impact of tumor stroma on drug response in breast cancer
Dittmer, J., & Leyh, B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.006 · Cited by 119
Multifaceted Roles of Interleukin-6 in Adipocyte–Breast Cancer Cell Interaction
Gyamfi, J., Eom, M., Koo, J. S., & Choi, J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2017.12.009 · Cited by 115
Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype
Hill, B. S., Pelagalli, A., Passaro, N., & Zannetti, A. (2017) · Oncotarget · doi:10.18632/oncotarget.20265 · Cited by 104
Helm, J. S., & Rudel, R. A. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02752-z · Cited by 119
De Luca, A., Lamura, L., Gallo, M., Maffia, V., & Normanno, N. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24212 · Cited by 102
“…able to induce in breast cancer cells the activation of signaling pathways that have been previously demonstrated to be involved in migration and invasion of cancer cells, such as the MEK/MAPK, the PI3K/AKT, and the STAT3 pathways [Badache and Hynes, 2001; Price et al., 2001; Sasser et al., 2007].”
BackgroundMethodMesenchymal stem cell signaling in cancer progression
Torsvik, A., & Bjerkvig, R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.005 · Cited by 100
Snyder, M., Huang, X.-Y., & Zhang, J. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.286245 · Cited by 99
Jobe, N. P., Rösel, D., Dvořánková, B., Kodet, O., Lacina, L., Mateu, R., Smetana, K., & Brábek, J. (2016) · Histochemistry and Cell Biology · doi:10.1007/s00418-016-1433-8 · Cited by 103
“CAFs have also been found to promote the metastasis of cancer cells at distant sites in an IL-6-depend- ent manner (Sasser et al. 2007).”
BackgroundSTAT3 can be activated through paracrine signaling in breast epithelial cells
Lieblein, J. C., Ball, S., Hutzen, B., Sasser, A. K., Lin, H.-J., Huang, T. H., Hall, B. M., & Lin, J. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-302 · Cited by 95
Self-citationSilverman, A. M., Nakata, R., Shimada, H., Sposto, R., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2165 · Cited by 93
Olsen, C. J., Moreira, J., Lukanidin, E. M., & Ambartsumian, N. S. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-444 · Cited by 88
Cytokine disbalance in common human cancers
Čulig, Z. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.12.010 · Cited by 103
Hendrayani, S., Al‐Khalaf, H. H., & Aboussekhra, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.594044 · Cited by 96
Notch signalling in cancer progression and bone metastasis
Sethi, N. S., & Kang, Y. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.497 · Cited by 97
“Independent studies have shown that IL-6 is associated with a poor prognosis in breast cancer (Zhang and Adachi, 1999; Salgado et al, 2003) and is capable of supporting tumour growth in stromal-dependent mechanisms (Sasser et al, 2007; Studebaker et al, 2008; Ara et al, 2009).”
BackgroundGallo, M., Luca, A. D., Lamura, L., & Normanno, N. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr159 · Cited by 86
Rhost, S., Hughes, É., Harrison, H., Rafnsdóttir, S., Jacobsson, H., Gregersson, P., Magnusson, Y., Fitzpatrick, P., Andersson, D., Berger, K., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1060-5 · Cited by 88
Rationally Designed Inhibitors Identify STAT3 N-Domain as a Promising Anticancer Drug Target
Timofeeva, O. A., Gaponenko, V., Lockett, S., Tarasov, S. G., Jiang, S., Michejda, C. J., Perantoni, A. O., & Tarasova, N. I. (2007) · ACS Chemical Biology · doi:10.1021/cb700186x · Cited by 80
Zang, C., Liu, X., Li, B., He, Y., Jing, S., He, Y., Wu, W., Zhang, B., Ma, S., Dai, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14495 · Cited by 79
Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer
Khalid, A., Wolfram, J., Ferrari, I., Mu, C., Mai, J., Yang, Z., Zhao, Y., Ferrari, M., Ma, X., & Shen, H. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955751513150923094709 · Cited by 81
Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment
Liu, Q., Yu, S., Li, A., Xu, H., Han, X., & Wu, K. (2017) · Tumor Biology · doi:10.1177/1010428317712445 · Cited by 84
Mesenchymal stromal cells as cancer promoters
Antoon, R., Overdevest, N., Saleh, A. H., & Keating, A. (2024) · Oncogene · doi:10.1038/s41388-024-03183-1 · Cited by 75
Fu, S., Chen, X. '., Lo, H., & Lin, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.026 · Cited by 79
Yamada, S., OKUMURA, N., Wei, L., Fuchs, B. C., Fujii, T., Sugimoto, H., Nomoto, S., Takeda, S., Tanabe, K. K., & Kodera, Y. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3779-2 · Cited by 77
Ah Receptor Antagonism Represses Head and Neck Tumor Cell Aggressive Phenotype
DiNatale, B. C., Smith, K., John, K., Krishnegowda, G., Amin, S. G., & Perdew, G. H. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0216 · Cited by 71
Snyder, M., Huang, J., Huang, X., & Zhang, J. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.591719 · Cited by 74
The Role of Inflammation in Inflammatory Breast Cancer
Fouad, T. M., Kogawa, T., Reuben, J. M., & Ueno, N. T. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_3 · Cited by 71
“Upon exposure of MCF-7 ER-positive cells to IL-6, tumor cell growth rates were enhanced by >two-fold (Sasser et al. 2007).”
BackgroundSegatto, I., Berton, S., Sonego, M., Massarut, S., Perin, T., Piccoli, E., Colombatti, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2195 · Cited by 72
So, K. A., Min, K., Hong, J. H., & Lee, J. K. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3122 · Cited by 72
New Advances in the Study of Bone Tumors: A Lesson From the 3D Environment
Cortini, M., Baldini, N., & Avnet, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00814 · Cited by 68
“As an example, the 3D assembly of ES cells with MSC elicits ligand-mediated activation of the insulin-like growth factor-1 receptor (IGF-1R), thereby mediating resistance to IGF-1R inhibitors (Santoro et al., 2017).”
BackgroundInfluentialThe effect of adipocyte–macrophage crosstalk in obesity-related breast cancer
Engin, A. B., Engin, A., & Gönül, İ. I. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0252 · Cited by 66
DiNatale, B. C., Schroeder, J. C., & Perdew, G. H. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20702 · Cited by 72
An IL-6 link between obesity and cancer
Ghosh, S. (2013) · Frontiers in Bioscience · doi:10.2741/e628 · Cited by 57
Park, J. S., Choi, S. Y., Lee, J.-H., Lee, M., Nam, E. S., Jeong, A. L., Lee, S., Han, S., Lee, M. S., Lim, J., et al. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0154-4 · Cited by 58
A Role for PML in Innate Immunity
Lunardi, A., Gaboli, M. P., Giorgio, M., Rivi, R., Bygrave, A. E., Antoniou, M. N., Drabek, D., Dzierzak, E. A., Fagioli, M., Salmena, L., et al. (2011) · Genes & Cancer · doi:10.1177/1947601911402682 · Cited by 65
In Vitro Co-Culture Models of Breast Cancer Metastatic Progression towards Bone
Arrigoni, C., Bersini, S., Gilardi, M., & Moretti, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091405 · Cited by 55
“IL-6 is a cytokine involved in a wide set of processes, including cell proliferation, angiogenesis and inflammation.”
BackgroundInfluentialAlbino, D., Civenni, G., Rossi, S., Mitra, A., Catapano, C. V., & Carbone, G. M. (2016) · Oncotarget · doi:10.18632/oncotarget.12525 · Cited by 55
IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment
Felcher, C. M., Bogni, E. S., & Kordon, E. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031809 · Cited by 63
“as myeloid-derived suppressor cells (MDSCs) [53], fibroblasts [38,47], lymphatic endothelial cells [54], and adipocytes [55] (Figure 1A).”
BackgroundResultInfluentialVegh, I., Grau, M. C., Gracia, M. Á. M., Grande, J., de la Torre, P., & Flores, A. I. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.71 · Cited by 54
Quagliariello, V., Iaffaioli, R. V., Armenia, E., Clemente, O., Barbarisi, M., Nasti, G., Berretta, M., Ottaiano, A., & Barbarisi, A. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25587 · Cited by 55
“Moreover, IL-6 iper secretion induces proliferation and a more aggressive phenotype in ER-positive breast cancer cells (Sasser et al., 2007) primarly trough STAT3 activation with induction of self-renewal of breast cancer stem cells (BCSCs) (Iliopoulos et al., 2011).”
BackgroundAryl Hydrocarbon Receptor Connects Inflammation to Breast Cancer
Guarnieri, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155264 · Cited by 52
Mesenchymal stem/stromal cells in breast cancer development and management
Tu, Z., & Karnoub, A. E. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.002 · Cited by 51
Barajas-Gómez, B. A., Rosas‐Carrasco, Ó., Morales-Rosales, S. L., Pedraza-Vázquez, G., González‐Puertos, V. Y., Juárez‐Cedillo, T., García, J. A., López‐Díazguerrero, N. E., Damián‐Matsumura, P., Königsberg, M., et al. (2016) · Cytokine · doi:10.1016/j.cyto.2016.12.001 · Cited by 53
Lagmay, J., London, W. B., Gross, T. G., Termuhlen, A. M., Sullivan, N. J., Axel, A. E., Mundy-Bosse, B. L., Ranalli, M. A., Canner, J. A., McGrady, P., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2953 · Cited by 46
“A role for IL-6 in the disease progression of several neoplasms such as multiple myeloma (5), colon cancer (6), renal cancer (7), Hodgkin's disease (8), non–Hodgkin's lymphoma (9), prostate cancer (10), melanoma (11), and breast cancer (12, 13) has been well documented.”
BackgroundSelf-citationMesenchymal Stromal Cells: Emerging Roles in Bone Metastasis
Graham, N., & Qian, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041121 · Cited by 47
Bergenfelz, C., Gaber, A., Allaoui, R., Mehmeti, M., Jirström, K., Leanderson, T., & Leandersson, K. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.346 · Cited by 43
“Breast tumours of the TN and ER PgR subtypes most often express pro-inflammatory proteins that activate STAT3 (Sasser et al, 2007).”
BackgroundInfluentialImproving Autologous Fat Grafting in Regenerative Surgery through Stem Cell-Assisted Lipotransfer
Debuc, B., Gendron, N., Cras, A., Rancic, J., Philippe, A., Cetrulo, C. L., Lellouch, A. G., & Smadja, D. M. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10568-4 · Cited by 55
Hsu, E., Kulp, S. K., Huang, H.-L., Tu, H., Salunke, S. B., Sullivan, N. J., Sun, D., Wicha, M. S., Shapiro, C. L., & Chen, C. (2015) · Neoplasia · doi:10.1016/j.neo.2015.06.001 · Cited by 47
“shRNA-mediated knockdown or pharmacological inhibition of ILK suppressed the expression of Notch1 and downstream targets in IL-6–producing MDA-MB-231 and SUM-159 cells, as well as MCF-7 cells (an IL-6–overexpressing stable clone of MCF-7) [17].”
BackgroundSelf-citationCheng, M. S., Liu, P., & Xu, L. X. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111159 · Cited by 47
Du, J., Zhou, L., Chen, X., Yan, S., Ke, M., Lu, X., Wang, Z., Yu, W., & Xiang, A. P. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.04.015 · Cited by 41
Chen, C., Liu, P., Duan, X., Cheng, M. S., & Xu, L. X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s193507 · Cited by 45
Chatterjee, S., Bhat, V., Berdnikov, A., Liu, J., Zhang, G., Buchel, E. W., Safneck, J. R., Marshall, A. J., Murphy, L. C., Postovit, L.-M. M., et al. (2019) · iScience · doi:10.1016/j.isci.2019.07.034 · Cited by 46
“….0005, and ****p < .00005, statistical significance was tested against the input controls). by activating signaling through their receptors, gp130 and CXCR1 (Ginestier et al., 2010; Iliopoulos et al., 2010; Korkaya et al., 2011; Sasser et al., 2007; Sheridan et al., 2006; Studebaker et al., 2008).”
BackgroundLeyh, B., Dittmer, A., Lange, T., Martens, J. W. M., & Dittmer, J. (2015) · Oncotarget · doi:10.18632/oncotarget.5624 · Cited by 41
Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women
Palmer, J. R., Castro‐Webb, N., Bertrand, K. A., Bethea, T. N., & Denis, G. V. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1903 · Cited by 46
Chukiatsiri, S., Siriwong, S., & Thumanu, K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110278 · Cited by 41
Hadji, P., Coleman, R. E., Gnant, M., & Green, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds169 · Cited by 40
Haider, M., Ridlmaier, N., Smit, D. J., & Taipaleenmäki, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062898 · Cited by 41
Metadata
- Authors
- Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M.
- Affiliations
- The Ohio State University (US)
- Center for Childhood Cancer Children's Research Institute Columbus Ohio USA
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-06-22
- Volume
- 21
- Issue
- 13
- Pages
- 3763-3770
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1973576115
- Cited by
- 222
- References
- 40
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 14 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 9 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 13 · 2015: 14 · 2014: 14 · 2013: 9 · 2012: 17
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Elsa U. Pardee Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- interleukin-6, estrogen receptor alpha, breast cancer, mesenchymal stem cells, STAT3 phosphorylation, bone metastasis, paracrine signaling, autocrine signaling, tumor growth, MCF-7 cells, IL-6 receptor
- MeSH terms
- Breast Neoplasms, Humans, Interleukin-6, Cell Line, Tumor, Estrogen Receptor alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.